Systematic Benchmarking of CRISPR-Cas9 Off-Target Prediction Tools Reveals Limitations and Implications for Preclinical Assessment.
Accurate identification of CRISPR-Cas9 off-target sites is essential for the safety assessment of genome-editing-based therapies. While numerous in silico prediction tools have been developed, their comparative performance and practical utility in preclinical workflows remain incompletely defined. We performed a system...